Literature DB >> 29491087

Number of Resected Lymph Nodes and Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy.

Jhe-Cyuan Guo1,2,3, Chia-Chi Lin1,4, Ta-Chen Huang1,4, Pei-Ming Huang5,6, Hung-Yang Kuo7, Chin-Hao Chang8, Chia-Chun Wang1,3, Jason Chia-Hsien Cheng1,4, Kun-Huei Yeh1,2,4, Chih-Hung Hsu9,4, Jang-Ming Lee10,6.   

Abstract

BACKGROUND: The association of extended lymph node (LN) dissection with improved outcomes in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who received preoperative chemoradiotherapy (CRT) followed by surgery is debatable. PATIENTS AND METHODS: We reviewed data from patients with esophageal cancer enrolled in three phase II clinical trials of preoperative paclitaxel and cisplatin-based CRT during 2000-2012. Patients with ESCC who underwent planned esophagectomy were enrolled. The number of resected LNs and other clinicopathological factors were analyzed regarding their impact on progression-free (PFS) and overall (OS) survival using Cox proportional hazards model.
RESULTS: In total, 139 patients were included. The median PFS and OS were 24.4 and 31.8 months, respectively. The median number of resected and positive LNs were 19 (range=2-96) and 0 (range=0-9), respectively. The mean number of positive LNs did not differ significantly among quartile groups of total resected LNs (quartile 1: 2-12, 2: 13-19, 3: 20-29, and 4: 30-96). The resected LN number analyzed as dichotomies divided by the median or as continuous variables was not associated with PFS or OS. However, in an exploratory analysis, patients of quartiles 2 and 3 had longer PFS and OS than those with quartiles of 1 and 4 in multivariate analysis (p=0.019 and 0.005, respectively).
CONCLUSION: Although extensive LN dissection was not associated with improved survival, resection of 13-29 LNs was associated with improved survival in patients with locally advanced ESCC receiving preoperative paclitaxel and cisplatin-based CRT. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Esophageal neoplasms; combined modality therapy; lymph node dissection; prognosis; squamous cell carcinoma

Mesh:

Year:  2018        PMID: 29491087     DOI: 10.21873/anticanres.12386

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  The Number of Harvested LNs Is an Independent Prognostic Factor in Lymph Node Metastasis-negative Patients Who Received Curative Esophagectomy.

Authors:  Toru Aoyama; Yosuke Atsumi; Shinnosuke Kawahara; Hiroshi Tamagawa; Ayako Tamagawa; Yukio Maezawa; Kazuki Kano; Masaaki Murakawa; Keisuke Kazama; Masakatsu Numata; Takashi Oshima; Norio Yukawa; Munetaka Masuda; Yasushi Rino
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Prognostic nomogram for Siewert type II adenocarcinoma of the esophagogastric junction patients with and without neoadjuvant radiotherapy: a retrospective cohort study.

Authors:  Zhenjiang Guo; Ning Wang; Fangzhen Liu; Qun Zhao
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

3.  Comparative analysis of clinical, treatment, and survival characteristics of signet ring cell and adenocarcinoma of esophagus.

Authors:  Zhang Peng; Feng Li; Zeng Cheng; Wu Kai; Zhao Song
Journal:  J Gastrointest Oncol       Date:  2021-08

4.  Does the lymph node yield affect survival in patients with esophageal cancer receiving neoadjuvant therapy plus esophagectomy? A systematic review and updated meta-analysis.

Authors:  Donglai Chen; Yiming Mao; Yuhang Xue; Yonghua Sang; Desen Liu; Yongbing Chen
Journal:  EClinicalMedicine       Date:  2020-07-31

5.  Comparison of minimally invasive Ivor Lewis esophagectomy and left transthoracic esophagectomy in esophageal squamous cell carcinoma patients: a propensity score-matched analysis.

Authors:  Qi Wang; Zixiang Wu; Tianwei Zhan; Shuai Fang; Sai Zhang; Gang Shen; Ming Wu
Journal:  BMC Cancer       Date:  2019-05-27       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.